251 related articles for article (PubMed ID: 25412416)
1. Aldosterone, parathyroid hormone, and the use of renin-angiotensin-aldosterone system inhibitors: the multi-ethnic study of atherosclerosis.
Brown J; de Boer IH; Robinson-Cohen C; Siscovick DS; Kestenbaum B; Allison M; Vaidya A
J Clin Endocrinol Metab; 2015 Feb; 100(2):490-9. PubMed ID: 25412416
[TBL] [Abstract][Full Text] [Related]
2. Human interventions to characterize novel relationships between the renin-angiotensin-aldosterone system and parathyroid hormone.
Brown JM; Williams JS; Luther JM; Garg R; Garza AE; Pojoga LH; Ruan DT; Williams GH; Adler GK; Vaidya A
Hypertension; 2014 Feb; 63(2):273-80. PubMed ID: 24191286
[TBL] [Abstract][Full Text] [Related]
3. Optimal antagonism of the Renin-Angiotensin-aldosterone system: do we need dual or triple therapy?
Werner C; Pöss J; Böhm M
Drugs; 2010 Jul; 70(10):1215-30. PubMed ID: 20568830
[TBL] [Abstract][Full Text] [Related]
4. Triple pharmacological blockade of the renin-angiotensin-aldosterone system in nondiabetic CKD: an open-label crossover randomized controlled trial.
Tylicki L; Rutkowski P; Renke M; Larczyński W; Aleksandrowicz E; Lysiak-Szydlowska W; Rutkowski B
Am J Kidney Dis; 2008 Sep; 52(3):486-93. PubMed ID: 18423812
[TBL] [Abstract][Full Text] [Related]
5. Effects of treatment with an angiotensin 2 receptor blocker and/or vitamin D3 on parathyroid hormone and aldosterone: A randomized, placebo-controlled trial.
Bislev LS; Langagergaard Rødbro L; Nørgaard Bech J; Bjerregaard Pedersen E; Rolighed L; Sikjaer T; Rejnmark L
Clin Endocrinol (Oxf); 2018 Nov; 89(5):656-666. PubMed ID: 29733445
[TBL] [Abstract][Full Text] [Related]
6. Fibroblast growth factor 23 and the antiproteinuric response to dietary sodium restriction during renin-angiotensin-aldosterone system blockade.
Humalda JK; Lambers Heerspink HJ; Kwakernaak AJ; Slagman MC; Waanders F; Vervloet MG; Ter Wee PM; Navis G; de Borst MH;
Am J Kidney Dis; 2015 Feb; 65(2):259-66. PubMed ID: 25278093
[TBL] [Abstract][Full Text] [Related]
7. Management of Renin-Angiotensin-Aldosterone System blockade in patients admitted to hospital with confirmed coronavirus disease (COVID-19) infection (The McGill RAAS-COVID- 19): A structured summary of a study protocol for a randomized controlled trial.
Aflaki M; Flannery A; Ferreira JP; Cheng MP; Kronfli N; Marelli A; Zannad F; Brophy J; Afillalo J; Huynh T; Giannetti N; Bessissow A; Ezekowitz JA; Lopes RD; Ambrosy AP; Craig M; Sharma A
Trials; 2021 Feb; 22(1):115. PubMed ID: 33546734
[TBL] [Abstract][Full Text] [Related]
8. Interactions between adrenal-regulatory and calcium-regulatory hormones in human health.
Brown JM; Vaidya A
Curr Opin Endocrinol Diabetes Obes; 2014 Jun; 21(3):193-201. PubMed ID: 24694551
[TBL] [Abstract][Full Text] [Related]
9. Influence of renin-angiotensin-aldosterone system-blocking drugs on peritoneal membrane in peritoneal dialysis patients.
Trošt Rupnik A; Pajek J; Guček A; Osredkar J; Kovač D; Bren A; Klančič D; Saksida S; Rus I; Globokar M; Drozg A; Lešnik M; Plešivčnik Z; Ekart R; Lopert S; Lindič J
Ther Apher Dial; 2013 Aug; 17(4):425-30. PubMed ID: 23931884
[TBL] [Abstract][Full Text] [Related]
10. A high aldosterone to renin ratio is associated with high serum parathyroid hormone concentrations in the general population.
Fischer E; Hannemann A; Rettig R; Lieb W; Nauck M; Pallauf A; Bidlingmaier M; Beuschlein F; Wallaschofski H; Reincke M
J Clin Endocrinol Metab; 2014 Mar; 99(3):965-71. PubMed ID: 24423297
[TBL] [Abstract][Full Text] [Related]
11. Aldosterone and parathyroid hormone interactions as mediators of metabolic and cardiovascular disease.
Tomaschitz A; Ritz E; Pieske B; Rus-Machan J; Kienreich K; Verheyen N; Gaksch M; Grübler M; Fahrleitner-Pammer A; Mrak P; Toplak H; Kraigher-Krainer E; März W; Pilz S
Metabolism; 2014 Jan; 63(1):20-31. PubMed ID: 24095631
[TBL] [Abstract][Full Text] [Related]
12. Parathyroid Hormone and the Use of Diuretics and Calcium-Channel Blockers: The Multi-Ethnic Study of Atherosclerosis.
Zaheer S; de Boer I; Allison M; Brown JM; Psaty BM; Robinson-Cohen C; Ix JH; Kestenbaum B; Siscovick D; Vaidya A
J Bone Miner Res; 2016 Jun; 31(6):1137-45. PubMed ID: 26748479
[TBL] [Abstract][Full Text] [Related]
13. Hypertension: renin-angiotensin-aldosterone system alterations.
Te Riet L; van Esch JH; Roks AJ; van den Meiracker AH; Danser AH
Circ Res; 2015 Mar; 116(6):960-75. PubMed ID: 25767283
[TBL] [Abstract][Full Text] [Related]
14. The Interplay Between the Renin-Angiotensin-Aldosterone System and Parathyroid Hormone.
Zheng MH; Li FX; Xu F; Lin X; Wang Y; Xu QS; Guo B; Yuan LQ
Front Endocrinol (Lausanne); 2020; 11():539. PubMed ID: 32973674
[TBL] [Abstract][Full Text] [Related]
15. The renin-angiotensin-aldosterone system blockade in patients with advanced diabetic kidney disease.
Bermejo S; García CO; Rodríguez E; Barrios C; Otero S; Mojal S; Pascual J; Soler MJ
Nefrologia (Engl Ed); 2018; 38(2):197-206. PubMed ID: 29102270
[TBL] [Abstract][Full Text] [Related]
16. Association of renin and aldosterone with ethnicity and blood pressure: the Multi-Ethnic Study of Atherosclerosis.
Rifkin DE; Khaki AR; Jenny NS; McClelland RL; Budoff M; Watson K; Ix JH; Allison MA
Am J Hypertens; 2014 Jun; 27(6):801-10. PubMed ID: 24436325
[TBL] [Abstract][Full Text] [Related]
17. Renin-Angiotensin-Aldosterone System Inhibitor Use and Mortality in Pulmonary Hypertension: Insights From the Veterans Affairs Clinical Assessment Reporting and Tracking Database.
Lahm T; Hess E; Barón AE; Maddox TM; Plomondon ME; Choudhary G; Maron BA; Zamanian RT; Leary PJ
Chest; 2021 Apr; 159(4):1586-1597. PubMed ID: 33031831
[TBL] [Abstract][Full Text] [Related]
18. Parathyroid hormone, aldosterone-to-renin ratio and fibroblast growth factor-23 as determinants of nocturnal blood pressure in primary hyperparathyroidism: the eplerenone in primary hyperparathyroidism trial.
Verheyen N; Fahrleitner-Pammer A; Pieske B; Meinitzer A; Belyavskiy E; Wetzel J; Gaksch M; Grübler MR; Catena C; Sechi LA; Van Ballegooijen AJ; Brandenburg VM; Scharnagl H; Perl S; Brussee H; März W; Pilz S; Tomaschitz A
J Hypertens; 2016 Sep; 34(9):1778-86. PubMed ID: 27379537
[TBL] [Abstract][Full Text] [Related]
19. Cardiorenal protection during chronic renin-angiotensin-aldosterone system suppression: evidences and caveats.
Ruiz-Hurtado G; Ruilope LM
Eur Heart J Cardiovasc Pharmacother; 2015 Apr; 1(2):126-31. PubMed ID: 27533982
[TBL] [Abstract][Full Text] [Related]
20. Combined blockade of renin-angiotensin-aldosterone system reduced all-cause but not cardiovascular mortality in dialysis patients: A mediation analysis and systematic review.
Li SM; He WB; Chen J; Cai QQ; Huang FF; Zhang K; Wang JF; Liu X; Huang H
Atherosclerosis; 2018 Feb; 269():35-41. PubMed ID: 29258005
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
